Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03707821 · ClinicalTrials.gov registry record · NA
Design Validation of Senofilcon A With New UV-blocking Additive
A NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 253
- Enrollment target
- 10
- Study locations
NCT03707821: Completed NA study of Visual Acuity, sponsored by Johnson & Johnson Vision Care.
NCT03707821 is a NA study of Visual Acuity that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 253 participants, above the 127-participant average among 20 other Visual Acuity trials with a reported enrollment target (99% higher). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03707821, a NA study of Visual Acuity, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 253 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a 2-visit, multi-site, partially subject-masked, 2-arm parallel, controlled, randomized and dispensing trial. Subjects will be randomized to one of two study lenses for the entire duration of the study. The study lenses will be worn for a period of 2 weeks each in a bilateral fashion.
Primary Outcome
Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/pos
Conditions Studied
Interventions
- DEVICE senofilcon A TEST Lens
- DEVICE senofilcon A CONTROL Lens
Study Locations (10)
Florida
- Maitland Vision Center - Maitland
- Tallahassee Eye Center - Tallahassee
Ohio
- ProCare Vision Centers - Granville
- Professional Vision Care, Inc - Westerville
California
- James T. Fujimoto, OD - Cupertino
Illinois
- Eyecare Associates LLP - Bloomington
Kansas
- Kannarr Eye Care - Pittsburg
Tennessee
- Bradley Hines, OD - Memphis
Texas
- Frazier Vision, Inc - Tyler
Wisconsin
- Ziegler Leffingwell Eyecare - New Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2018-11-01 |
| Phase | NA |
What the finished NCT03707821 record still lists
NCT03707821 is an interventional study that assigns participants to a tested intervention. The registered 253 participants enrollment target is mid-sized for trials with a published cap, above the 127-participant average among 20 other Visual Acuity trials with a reported enrollment target (99% higher).
The record links to 1 condition, with Visual Acuity appearing as the primary indexed condition, and to 2 interventions - of which senofilcon A TEST Lens is the first listed.
NCT03707821 lists 10 locations in 8 states (Florida, Ohio, California).
Frequently Asked Questions
What is clinical trial NCT03707821 about?
NCT03707821 is a clinical study titled "Design Validation of Senofilcon A With New UV-blocking Additive". This is a 2-visit, multi-site, partially subject-masked, 2-arm parallel, controlled, randomized and dispensing trial. Subjects will be randomized to one of two study lenses for the entire duration of the study. The study lenses will be worn for a period of 2 weeks each in a bilateral fashion.
What is the current status of trial NCT03707821?
This trial is currently completed. It is a NA study. The enrollment target is 253 participants. The study started on 2018-10-01. Estimated completion is 2018-11-01.
What conditions does trial NCT03707821 study?
This clinical trial studies the following conditions: Visual Acuity.
What interventions are being tested in trial NCT03707821?
The interventions under investigation include: senofilcon A TEST Lens (DEVICE), senofilcon A CONTROL Lens (DEVICE).
Who is sponsoring clinical trial NCT03707821?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03707821 being conducted?
This trial has 10 study locations across California, Florida, Illinois, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Visual Acuity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03707821's enrollment target sits among peer trials
253 3rd of 20 higher than 18 of 20 other Visual Acuity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Visual Acuity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Effect of Scatter on Visual Performance
RECRUITING · NA
-
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 2
COMPLETED · NA
-
Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses
COMPLETED · NA
-
Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
COMPLETED · NA
-
Clinical Evaluation of Approved Contact Lenses
COMPLETED · NA
-
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI